Eli Lilly Approaches Agreement to Acquire Psychedelic Drug Developer AtaiBeckley

Eli Lilly is advancing toward a deal to acquire AtaiBeckley, a company focused on psychedelic therapeutics. Bloomberg News reports that representatives from both firms recently initiated discussions and are working on the terms of the agreement. AtaiBeckley specializes in psilocybin‑based treatments and has developed drug candidates that show promise for depression, anxiety, and post‑traumatic stress disorder. The company’s pipeline could add a new therapeutic area to Lilly’s existing portfolio. For Lilly, the acquisition would strengthen its biotechnology and neurological drug‑development strategy, providing expertise in clinical research and commercial distribution of psychedelic medicines. Additionally, AtaiBeckley’s research facilities and specialist team could expand Lilly’s R&D capabilities. Regulatory and financial due diligence remains to be completed before final approval. Both parties plan further negotiations to clarify the terms and cost structure of the transaction. Upon completion, the companies intend to integrate AtaiBeckley’s products and research activities into Lilly’s global network. This is not investment advice.